https://prabadinews.com/
  • October 8, 2026
  • Last Update July 17, 2026 9:28 pm
  • United States of America

Shifting Therapeutic Urgency and TKI Strategy

Shifting Therapeutic Urgency and TKI Strategy

An expert discusses how different tyrosine kinase inhibitor (TKI) mechanisms of action, including asciminib’s allosteric binding vs traditional ATP-competitive inhibitors, influence treatment selection based on off-target effects and adverse effect profiles, with patients with advanced-phase chronic myeloid leukemia (CML) requiring second-generation or higher TKIs for faster response rates.

administrator

Related Articles